Autolus Therapeutics plc
AUTL- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001730463
In the last 90 days, Autolus Therapeutics plc insiders filed 0 open-market purchases and 1 sale; 83 institutions reported holding it in 13F filings for Q2 2026, worth $212.0M in total; no superinvestor holds it.
13F holders, Q4 2025
Institutional positions in Autolus Therapeutics plc as of Dec 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 89
- −5 vs. Q3 2025
- Shares held
- 139.3M
- −1.89M (−1.3%) vs. Q3 2025
- Total value
- $277.1M
- +$47.1M (+20.5%) vs. Q3 2025
- New holders
- 14
- 25 more added
- Sold out
- 19
- 28 more reduced
2 institutions that held it in Q3 2025 haven't filed for Q4 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting AUTL on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 83 | $212.0M |
| Q1 2026 | 84 | $184.4M |
| Q4 2025 | 89 | $277.1M |
| Q3 2025 | 96 | $235.7M |
| Q2 2025 | 94 | $378.6M |
| Q1 2025 | 95 | $261.0M |
| Q4 2024 | 110 | $395.4M |
| Q3 2024 | 101 | $648.5M |
| Q2 2024 | 111 | $620.0M |
| Q1 2024 | 120 | $1.12B |
| Q4 2023 | 99 | $746.6M |
| Q3 2023 | 71 | $258.1M |
| Q2 2023 | 69 | $260.4M |
| Q1 2023 | 65 | $195.1M |
| Q4 2022 | 71 | $204.2M |
| Q3 2022 | 66 | $105.7M |
| Q2 2022 | 67 | $143.9M |
| Q1 2022 | 66 | $228.6M |
| Q4 2021 | 73 | $272.3M |
| Q3 2021 | 59 | $164.2M |
| Q2 2021 | 69 | $169.6M |
| Q1 2021 | 63 | $129.4M |
Institutions, Q4 2025
Shares, value and share of portfolio for each institution holding Autolus Therapeutics plc; share changes are against Q3 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Aquatic Capital Management LLC | 0 | $0 | 0.00% | −104,684−100.0% | Sold out |
| Squarepoint Ops LLC | 0 | $0 | 0.00% | −91,957−100.0% | Sold out |
| Aigen Investment Management, LP | 0 | $0 | 0.00% | −65,617−100.0% | Sold out |
| Virtus Investment Advisers, Inc. | 0 | $0 | 0.00% | −52,924−100.0% | Sold out |
| Mariner, LLC | 0 | $0 | 0.00% | −10,322−100.0% | Sold out |
| Group One Trading, L.P. | 0 | $0 | 0.00% | −8,381−100.0% | Sold out |
| Barclays PLC | 0 | $0 | 0.00% | −7,883−100.0% | Sold out |
| Principal Securities, Inc. | 0 | $0 | 0.00% | −37−100.0% | Sold out |
| AXA Investment Managers S.A. | – | – | – | – | Not filed |
| Cubist Systematic Strategies, LLC | – | – | – | – | Not filed |